18:09:10 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbioteknikbolag som drivs av cannabinoider. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.

Kalender

2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-04-16 12:00:00

COPENHAGEN, Denmark, 16 April 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") is pleased to announce the employment of Helle Bjerregaard. Helle Bjerregaard has been appointed as Head of Quality (HOQ) at DanCann Pharma A/S.

Helle Bjerregaard joins the DanCann Pharma team as the company's Head of Quality. She is a certified Quality Management professional and will oversee implementing relevant quality systems according to global standards such as GMP and ISO 9001.

Helle Bjerregaard has a proven track record within Quality Management and joins DanCann Pharma from a job as quality coordinator at the Danish Safety Authority. Prior employments include a position at Pfizer and overall, she has more than 20 years of experience from working with Quality, Food Safety, Working environment and general environmental issues. Helle Bjerregaard is looking forward to her participation in the development of DanCann Pharma as an important contributor on the Danish and international markets.  

Helle explains:" DanCann Pharma is a young and ambitious company with a very dedicated team of employees. It was an easy decision for me to join and be part of the company. The next period will consist of several important milestones and fortunately I can contribute with my track-record, expertise, and knowledge regarding Quality Management. I am very proud to be a part of the DanCann Pharma team who share a such strong passion for improving quality of life for patients with challenges. I look forward to the exciting months to come."

Jeppe Krog Rasmussen, CEO at DanCann Pharma elaborates: "Helle's know-how and experience with Quality Management and global standards will be an essential asset for DanCann Pharma and will help us take a huge step towards fulfilling our ambitions of having a state-of-the-art organization with second to none facilities and employees. Quality Management is an important means in reaching our goals and we are quite excited about the appointment of Helle as head of this department."

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com